Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS

Inclusion Criteria:

* Patients with refractory AML Refractory AML is defined as follows;

  1. Primary refractory: failure to achieve complete remission (CR) after 2 cycles of induction chemotherapy; or, in patient ≥65 years of age, progressive AML after treatment with hypomethylating agent (increase in peripheral blood blast by 50% or increase in bone marrow blast by 25%)
  2. Relapse then refractory: recurrence of AML, which is refractory to standard salvage chemo therapy; or, in patient ≥65 years of age, to hypomethylating agent
  3. AML in ≥2 relapses
* Patients should be 19 years of age or older
* Patients should have Karnofsky performance scale ≥70
* Patients and cell donors must understand fully and sign informed consent forms

Exclusion Criteria:

* Pregnant or lactating women
* Patient with abnormal liver function (total bilirubin ≥ 5.0 mg/dl, AST ≥ 5 times upper normal limits)
* Patients with abnormal renal function (creatinine ≥ 3.0 mg/dl)
* Patients with clinically-evident cardiac or pulmonary dysfunction
* Patients with infection that is progressive despite appropriate anti-microbial treatment
* Patients with hypersensitivity to gentamicin
* Patients who had received allogeneic cell therapy previously.